Talking Trials, Investment And Fluid-Overload Treatments With Sequana Medical
Executive Summary
Sequana Medical is simultaneously developing both drug and device treatments for fluid overloads in the body. Medtech Insight spoke to the company’s CEO about their trials and the challenges of raising cash in 2023.
You may also be interested in...
Cordio Medical Is Using Patients’ Voices To Spot Heart Failure
As fluid builds up in the lungs, the “engine” of a patient’s voice is smothered. Medtech Insight spoke to Cordio Medical’s CEO about how the company’s smartphone-based software could warn clinicians almost three weeks in advance of decompensation.
Exec Chat: Sequana Medical Pursues Dual Device-Drug Strategy For Fluid Overload
Speaking to Medtech Insight, Sequana Medical’s CEO discussed the company’s two technologies for combating fluid overload whilst explaining that, sometimes, chasing approval as a drug can be the best way to ensure easy market access.
News We’re Watching – US FDA Updates, Digital Therapeutics Legislation, AI Endoscopies, Monkeypox EUA, And New AdvaMed Chair
The US Food and Drug Administration recently issued updates regarding improvements to its online submissions portal, enhancements to its electronic medical device reporting system, pediatric X-ray guidance, expanded indications for a popular breathing device, and mammogram guidelines; and more news we’re watching.